Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

FDA announces recall for Johnson & Johnson devices due to cybersecurity risk—customers urged to act
The FDA and Johnson & Johnson MedTech are telling customers to keep the devices in a secure environment until they can be disabled from all networks.
New expert guidelines examine the use of temporary MCS during heart surgery
Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.
FDA approves subcutaneous diuretic treatment for heart failure-related edema
The newly approved drug-device combination helps patients manage their own treatment from the comfort of home.
Obesity drugs under review: Semaglutide, tirzepatide, naltrexone/bupropion all boost heart health
The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others.
ACC calls for more screening in new scientific statement on inflammation
The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote.

cybersecurity hacker ransomware cyber data breach

FDA announces recall for Johnson & Johnson devices due to cybersecurity risk—customers urged to act

The FDA and Johnson & Johnson MedTech are telling customers to keep the devices in a secure environment until they can be disabled from all networks.

New expert guidelines examine the use of temporary MCS during heart surgery

Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.

FDA approves subcutaneous diuretic treatment for heart failure-related edema

The newly approved drug-device combination helps patients manage their own treatment from the comfort of home.

obesity semaglutide tirzepatide GLP-1 drugs weight loss

Obesity drugs under review: Semaglutide, tirzepatide, naltrexone/bupropion all boost heart health

The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others.

A new ACC consensus document of coronary inflammation calls for wider use of hs-CRP testing to identify more patients with residual heart attack risk, even if they are optimal statin therapy.

ACC calls for more screening in new scientific statement on inflammation

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote.

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, director of prevention, associate director, Barbra Streisand Women's Heart Center, Cedars-Sinai, and past president of the American Society for Preventive Cardiology (ASPC), was co-chair on a new joint scientific statement from the Heart Failure Society of America, and the ASPC on the need to boost prevention efforts for heart failure. She explains the new scientific statement that calls for greater prevention efforts in heart failure.

Putting more emphasis on prevention in heart failure care

Martha Gulati, MD, co-chair on a new joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology, discusses the dire need she sees to boost prevention efforts for heart failure.

Vulnerable, but treatable: Semaglutide reduces symptoms in high-risk heart failure patients

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

heart data research doctor cardiologist AI

America’s heart failure epidemic is getting worse

Approximately one in four Americans will develop heart failure in their lifetime, according to a new report from the Heart Failure Society of America. What can be done to combat this worrisome trend?